{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:25:52Z","timestamp":1764084352955,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtha.2023.10.026","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T22:23:41Z","timestamp":1706826221000},"page":"352-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies\u2014generational enhancement"],"prefix":"10.1016","volume":"22","author":[{"given":"David","family":"Lillicrap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.10.026_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog Alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib4","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.10.026_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ymthe.2023.03.001","article-title":"Two gene therapies for hemophilia available: now what?","volume":"31","author":"Pierce","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.10.026_bib9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.026_bib11","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.10.026_bib14","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib16","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/hae.14847","article-title":"Dilemmas on emicizumab in children with haemophilia A: a survey of strategies from PedNet centres","volume":"29","author":"Ranta","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.10.026_bib17","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1182\/blood-2022-163554","article-title":"Mim8 clinical development program: an overview of the Frontier studies","volume":"140","author":"Seremetis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A\u00a0factor VIIIa\u2013mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.10.026_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state","volume":"22","author":"Teranishi-Ikawa","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.10.026_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.10.026_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2222441","article-title":"Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A","volume":"15","author":"Koga","year":"2023","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.jtha.2023.10.026_bib22","article-title":"Safety, pharmacokinetics and pharmacodynamics of single subcutaneous injection of NXT007 an emicizumab-based next generation bispecific antibody in healthy volunteers (NXTAGE Study)","volume":"69","author":"Shima","year":"2023","journal-title":"ISTH Congress Abstract OC"},{"key":"10.1016\/j.jtha.2023.10.026_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A\u00a0hemophilia A mouse model for the in\u00a0vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:39:53Z","timestamp":1761536393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1538783623007961"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.10.026","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia A treatment innovation: factor VIII mimetic bispecific antibodies\u2014generational enhancement","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}